Prelude Capital Management, LLC Legend Biotech Corp Transaction History

Prelude Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$57.25 - $69.74 $153,830 - $187,391	2,687 Added 26.03%	13,009 $782,000
Q3 2023 Nov 14, 2023	BUY	$63.16 - $76.5 $347,380 - $420,750	5,500 Added 114.06%	10,322 $693,000
Q2 2023 Aug 14, 2023	SELL	$46.28 - $75.01 $517,317 - $838,461	-11,178 Reduced 69.86%	4,822 $332,000
Q1 2023 May 15, 2023	SELL	$43.42 - $57.37 $243,152 - $321,272	-5,600 Reduced 25.93%	16,000 $771,000
Q4 2022 Feb 14, 2023	BUY	$38.8 - $55.46 $139,680 - $199,656	3,600 Added 20.0%	21,600 $1.08 Million
Q2 2022 Aug 15, 2022	BUY	$33.54 - $55.0 $11,739 - $19,250	350 Added 1.98%	18,000 $990,000
Q1 2022 May 16, 2022	BUY	$31.02 - $48.18 $547,503 - $850,377	17,650 New	17,650 $641,000

205

74.5M

371K

387K

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6.7B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.